× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy



meta|Evidence breast cancer

Living evidence synthesis
about last generation of breast cancer treatments

Member of the meta|Evidence galaxy

Pathology browse pathologies  

Latest studies

Li, 2024

breast cancer - triple negative

camrelizumab plus SOC

KEYNOTE-119 PD-L1 positive (CPS = 1 or more), 2019

la/mBC - TNBC - L2 - PDL1 positive

pembrolizumab alone

KEYNOTE-119 PD-L1 positive (CPS = 10 or more), 2019

la/mBC - TNBC - L2 - PDL1 positive

pembrolizumab alone

IMpassion-132, PD-L1 positive population, 2024

la/mBC - TNBC - L2 - PDL1 positive

atezolizumab plus SoC

Treatments browse treatments

121
treatments 		  121
studies 		  218
references
This project is supported by H2020 Qualitop, an EU-funded project, Hospices Civils de Lyon and CNRS UMR5558 LBBE.
     

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons